Zevra Therapeutics, Inc. (ZVRA) Misses Q2 EPS by 2c

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) reported Q2 EPS of ($0.48), $0.02 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $4.4 million versus the consensus estimate of $4.41 million.

For earnings history and earnings-related data on Zevra Therapeutics, Inc. (ZVRA) click here.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Full Circle Lithium closes $5.14M private placement
• Mosaic sets pricing for tender offers on up to $1.4B in debt